Global Bone Marrow Transplant Market 2017-2021

Overview of the global bone marrow transplant market

According to Technavio’s market research report, the global bone marrow transplant market will grow at a CAGR of more than 5% during the forecast period. The increasing federal funding in regenerative medicines is one of the key drivers that will stimulate growth in the market during the projected period. Research institutes and small companies cannot always afford the research and clinical trials of regenerative medicines because they require huge investments. The increasing importance of regenerative medicines is encouraging federal organizations to offer financial support to develop regenerative therapies. The NIH and the California Institute for Regenerative Medicine (CIRM) are some of the organizations that offer funds in the US. NIH is also providing funds for studies related to iPSC technology.

The increasing consumption of tobacco and alcohol and rising prevalence of various types of cancers is driving the market for bone marrow transplant in EMEA. Bone marrow registry helps to improve the scarcity of donor and better genetical match. The increase in bone marrow registry will boost the number of donors across the regions and result in better medical logistics and storage.

Competitive landscape and key vendors

The global bone marrow transplant market is characterized by the presence of many key vendors. These vendors compete against each other based on factors such as inorganic strategies, pricing strategies, expansion of collection centers. The increased inorganic growth strategies and expansion of collection centers will strengthen the competitive scenario of the market.

Key vendors in this market are -

• AllCells
• Lonza
• Merck
• Sanofi

Other prominent vendors in the market include Athersys, Beike Biotechnology, BioTime, bluebird bio, Caladrius, Cellular Biomedicine Group, Cellular Dynamics International, Cesca Therapeutics, CHA Biotech, Chugai Pharmaceutical, CORESTEM, Gamida Cell, Global Stem Cells Group, Hemostemix, Histocell, Mesoblast, TiGenix, and Translational Biosciences.

Segmentation by transplant type and analysis of the bone marrow transplant market

• Autologous bone marrow transplant
• Allogeneic bone marrow transplant

An autologous bone marrow transplant is highly preferred by surgeons as they involve fewer complications. The segment will continue to grow during the predicted period due to the rising prevalence of diseases such as Hodgkin and non-Hodgkin lymphomas, multiple myeloma, and autoimmune diseases.

Segmentation by indication and analysis of the bone marrow transplant market

• Multiple myeloma
• Acute leukemia
• Hodgkin lymphoma
• Non-hodgkin lymphoma
• Solid tumors

Multiple myeloma is a type of cancer formed by malignant plasma cells. The segment will grow from 2017 to 2021 because autologous bone marrow transplants are highly preferred over allogeneic bone marrow transplants for the treatment of multiple myeloma.

Key questions answered in the report include

• What will the market size and the growth rate be in 2021?
• What are the key factors driving the global bone marrow transplant market?
• What are the key market trends impacting the growth of the global bone marrow transplant market?
• What are the challenges to market growth?
• Who are the key vendors in the global bone marrow transplant market?
• What are the market opportunities and threats faced by the vendors in the global bone marrow transplant market?
• What are the trending factors influencing the market shares of the Americas, APAC, and EMEA?
• What are the key outcomes of the five forces analysis of the global bone marrow transplant market?

Technavio also offers customization on reports based on specific client requirement